摘要
目的评价孟鲁司特钠治疗支气管哮喘(BA)的疗效及对气道上皮细胞白介素-25(IL-25)和α-平滑肌肌动蛋白(α-SMA)的影响。方法将我院2014年4月至2017年4月收治的BA患者114例随机分为对照组和观察组,各57例。两组均予以常规治疗,观察组加服孟鲁司特钠。比较两组的治疗效果。结果治疗后,两组的FEV_1、FEV_1/FVC、PEF水平,以及气道上皮细胞IL-25和α-SMA mRNA水平均显著优于治疗前,且观察组优于对照组(P<0.05)。治疗期间,两组均未出现不良反应。观察组治疗愈显率明显高于对照组(P<0.05)。结论孟鲁司特钠可有效改善BA患者临床症状,疗效明确,安全性高。
Objective To evaluate the effect of montelukast sodium in the treatment of bronchial asthma(BA)and its effects on airway epithelial cell IL-25andα-SMA.Methods A total of114patients with BA treated in our hospital from April2014to April2017were randomly divided into control group and observation group,with57cases in each group.All the patients were given conventional treatment,and the observation group added montelukast sodium.The curative effects of the two groups were compared.Results After treatment,the FEV1,FEV1/FVC and PEF levels and the levels of airway epithelial cell IL-25andα-SMA mRNA of the two groups were better than those before treatment and those of the observation group were better than the control group(P<0.05).During treatment,no adverse reactions occurred in both groups.The cure rate of the observation group was higher than that of the control group(P<0.05).Conclusion Montelukast sodium can effectively improve the clinical symptoms of BA patients,with specific curative effect and high safety.
作者
高晓平
GAO Xiao-ping(Xi'an Aerospace General Hospital, Xi'an 710100, China)
出处
《临床医学研究与实践》
2018年第6期36-37,共2页
Clinical Research and Practice
